We have been representing patients and their family in drug injury lawsuits for the past 15 years and this is our main practice area.
Drug injury legal compensation cases involve personal injury or wrongful death claims filed on behalf of people who, unfortunately, experienced a serious side effect, had an adverse drug reaction, or died from their use of a prescription medication.
Given our many years of experience handling these types of lawsuits we know drug injury cases deserve special attention.
Drug injury claims have a personal aspect which must be appreciated and respected by the attorney handling your case. At our law firm, we do not underestimate nor lose sight of the trust which is being placed in us by clients when they select us to represent them for their lawsuit against the responsible pharmaceutical company.
We will handle your drug injury case not only competently and professionally, but with genuine care and understanding. Any inquiries from our clients are responded to promptly, and telephone calls are always returned without delay.
If you, relatives, or friends need legal advice or legal representation for a personal injury lawsuit or a wrongful death lawsuit involving a drug side effect, the Law Offices of Thomas J. Lamb is here to help.
We encourage you to submit a Drug Injury Law Case Review — it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, or some other lawyer — about your case based on his many years of experience.
We handle these drug injury cases on a contingency fee basis, meaning that there is no payment for our legal services until we are successful in getting legal compensation for you.
While our office is in Wilmington, North Carolina, we have successfully handled drug injury lawsuits for people all over the United States.
It is important to note that we do not put our clients into large class actions. Rather we favor an individual lawsuit approach, which allows us to give personal attention to each of our clients, from start to finish.
Legal & Medical News: Featured Article
Some newer oral anticoagulants have been associated with bleeding-related adverse reactions including gastrointestinal and intracranial bleeds. And that problem is the primary complaint that the Institute for Safe Medications (ISMP) has with these blood thinners.
The ISMP QuarterWatch published on September 23, 2015 includes an examination of the safety profiles of Eliquis, Pradaxa, and Xarelto, which are characterized as “novel” oral anticoagulants. Savaysa is not included in this ISMP study because it draws on FDA data from the second half of 2014 and Savaysa was not approved by the FDA until January 2015.
This September 2015 edition of the ISMP QuarterWatch publication then goes on to cover a safety issue with Savaysa, Eliquis, Pradaxa, and Xarelto that has not received much attention: The effect of platelet inhibitors in combination with those new anticoagulants.
From the ISMP report, we get these 3 points about the effect of platelet inhibitors:
1. The adverse event data for 2014 raised questions about why no clear guidelines existed about when or even whether patients should take two different kinds of drugs that inhibited the formation of blood clots. The anticoagulants reduce blood clot formation by inhibiting the enzyme that triggers the formation of fibrin threads that help seal the platelets that aggregate to plug bleeding site. Aspirin, clopidogrel, and other nonsteroidal anti-inflammatory drugs inhibit the aggregation of platelets.
2. In the adverse event data, we found that concomitant therapy with platelet inhibitors increased the odds of a hemorrhage event by threefold (OR 3.01 p < 0.01). The increased risk was found across all three of the novel anticoagulants and warfarin.
3. The prescribing information for all three drugs [Xarelto, Pradaxa, and Eliquis] contains no guidance on the concomitant use of antiplatelet agents other than a warning that an increased risk of bleeding was observed.
It seems sensible that the FDA should require studies be done to develop clear and definitive guidelines for whether to use these new anticoagulant drugs at the same time, i.e., concomitant use, that a patient is taking one or more of the platelet inhibitors.
Earlier articles by attorney Tom Lamb on the Side Effects Blog:
- No Antidotes For Eliquis, Savaysa, And Xarelto To Stop Acute Bleeding
- Invokana Label Gets New Warnings About Increased Bone Fracture Risks
- Merck Fosamax – Femur Fracture Lawsuits Wait For Appeals Court Rulings
- After PML Warnings, Gilenya Has Cancer Side Effects Says Health Canada
- Xarelto – Liver Side Effects: Will New Warning Be Added To Drug Label?
- Diabetes Drugs Like Januvia Linked To Severe Joint Pain Side Effects
- Despite Benefits Of Jardiance, There Are Still Safety Concerns
- New Blood-Thinner Savaysa Has No Antidote To Reverse Acute Bleeding